Literature DB >> 20803286

Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.

Jindrich Kopecký1, Peter Priester, Ladislav Slovácek, Jirí Petera, Otakar Kopecký, Zuzana Macingova.   

Abstract

BACKGROUND: Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy. Serious hematologic complications are rarely reported. CASE REPORT AND
RESULTS: The authors present the case of a 61-year-old female patient with glioblastoma multiforme treated with external-beam radiation therapy and concomitant temozolomide. After completion of treatment, the patient developed symptoms of serious aplastic anemia that eventually led to death due to prolonged neutro- and thrombocytopenia followed by infectious complications.
CONCLUSION: Lethal complications following temozolomide are, per se, extremely rare, however, a total of four other cases of aplastic anemia have been reported in the literature so far.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20803286     DOI: 10.1007/s00066-010-2132-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  15 in total

1.  Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.

Authors:  J Lee Villano; Cindy A Collins; Elisabet E Manasanch; Charulata Ramaprasad; Koen van Besien
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

2.  A rare case of aplastic anemia caused by temozolomide.

Authors:  Benjamin J George; Jessica B Eichinger; Thomas J Richard
Journal:  South Med J       Date:  2009-09       Impact factor: 0.954

3.  Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.

Authors:  Martin Kocher; Sabine Kunze; Hans-Theodor Eich; Robert Semrau; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2005-03       Impact factor: 3.621

4.  Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?

Authors:  Emmanouil Fokas; Ulrich Wacker; Markus W Gross; Martin Henzel; Elitsa Encheva; Rita Engenhart-Cabillic
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

5.  The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.

Authors:  Georgios Iliadis; Panagiotis Selviaridis; Anna Kalogera-Fountzila; Anna Fragkoulidi; Dimos Baltas; Nikolaos Tselis; Athanasios Chatzisotiriou; Despina Misailidou; Nikolaos Zamboglou; George Fountzilas
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

6.  Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.

Authors:  Maria Grazia Fabrini; Franco Perrone; Lucia De Franco; Francesco Pasqualetti; Silvia Grespi; Riccardo Vannozzi; Luca Cionini
Journal:  Strahlenther Onkol       Date:  2009-08-04       Impact factor: 3.621

Review 7.  Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.

Authors:  Nimit Singhal; Sudarshan Selva-Nayagam; Michael P Brown
Journal:  J Neurooncol       Date:  2007-05-26       Impact factor: 4.130

Review 8.  Temozolomide in malignant gliomas: current use and future targets.

Authors:  J Lee Villano; Tara E Seery; Linda R Bressler
Journal:  Cancer Chemother Pharmacol       Date:  2009-06-19       Impact factor: 3.333

Review 9.  Cognitive deficits in adult patients with brain tumours.

Authors:  Martin J B Taphoorn; Martin Klein
Journal:  Lancet Neurol       Date:  2004-03       Impact factor: 44.182

10.  Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.

Authors:  J A B van Genugten; P Leffers; B G Baumert; H Tjon-A-Fat; A Twijnstra
Journal:  J Neurooncol       Date:  2009-07-07       Impact factor: 4.130

View more
  9 in total

1.  Radiotherapy of splenomegaly : a palliative treatment option for a benign phenomenon in malignant diseases.

Authors:  Jan Kriz; Oliver Micke; Frank Bruns; Uwe Haverkamp; Ralph Mücke; Ulrich Schäfer; Heinrich Seegenschmiedt; Rolf-Peter Müller; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2011-03-07       Impact factor: 3.621

2.  Temozolomide-induced liver damage. A case report.

Authors:  F Becker; M Hecht; J Schmidtner; S Semrau; R Fietkau
Journal:  Strahlenther Onkol       Date:  2014-01-24       Impact factor: 3.621

Review 3.  Methodologies in creating skin substitutes.

Authors:  Mathew N Nicholas; Marc G Jeschke; Saeid Amini-Nik
Journal:  Cell Mol Life Sci       Date:  2016-05-06       Impact factor: 9.261

4.  Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience.

Authors:  Arnulf Mayer; Carina Schwanbeck; Clemens Sommer; Marcus Stockinger; Alf Giese; Mirjam Renovanz; Peter Vaupel; Heinz Schmidberger
Journal:  Strahlenther Onkol       Date:  2015-05-30       Impact factor: 3.621

5.  Radiotherapy with and without temozolomide in elderly patients with glioblastoma.

Authors:  M Niyazi; S B Schwarz; B Suchorska; C Belka
Journal:  Strahlenther Onkol       Date:  2012-01-11       Impact factor: 3.621

6.  Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme.

Authors:  Felipe Batalini; Matthew R Kaufmann; Gabriel Francisco Aleixo; Reed Drews
Journal:  BMJ Case Rep       Date:  2019-06-29

7.  Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.

Authors:  Albert K Park; Anem Waheed; Deborah A Forst; Hanny Al-Samkari
Journal:  Neuro Oncol       Date:  2022-06-01       Impact factor: 13.029

8.  Temozolomide-induced Aplastic Anemia Treated with Eltrombopag and Granulocyte Colony Stimulating Factor: A Report of a Rare Complication.

Authors:  Shauna L Newton; Kadra Kalamaha; Hermina D Fernandes
Journal:  Cureus       Date:  2018-09-18

Review 9.  The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment.

Authors:  Yaxin Huang; Guohui Sun; Xiaodong Sun; Feifan Li; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.